| Name | (2S)-2-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-N-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide |
|---|---|
| Synonyms | Lauryl-LF 11 |
| Description | SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
hNK1:0.62 nM (IC50) hNK2:0.52 μM (Ki) hNK3:3.4 μM (Ki) |
| In Vitro | SDZ NKT 343 shows a markedly lower affinity at rat NK1 receptors in whole forebrain membranes (IC50=451+139 nM)[1]. SDZ NKT 343 shows weak affinity to human NK2 and NK3 receptors in transfected Cos-7 cells (Ki of 0.52+0.04 μM and 3.4+1.2 μM respectively)[1]. |
| In Vivo | SDZ NKT 343 antagonized [Sar9]SP sulphone-evoked bronchoconstriction (70% reduction at 0.4 mg/kg, i.v.) in anaesthetized guinea-pigs[1]. |
| References |
| Density | 1.327g/cm3 |
|---|---|
| Boiling Point | 892.8ºC at 760mmHg |
| Molecular Formula | C33H33N5O5 |
| Molecular Weight | 579.64600 |
| Flash Point | 493.8ºC |
| Exact Mass | 579.24800 |
| PSA | 127.57000 |
| LogP | 6.05540 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.676 |